Get started
Author

Sasanka M. Handunnetti

Observed names: S.M. Handunnetti, Sasanka Handunnetti, Sasanka M Handunnetti
Observed institutions: The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, The Alfred Hospital, St Vincent's Hospital Melbourne, Victorian Comprehensive Cancer Centre, Princess Alexandra Hospital
ORCID: 0000-0001-8790-4675
Observed ORCID: 0000-0001-8790-4675
OpenAlex ID: A5042814601
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
2018 · Constantine S. Tam, Mary Ann Anderson, et al. · New England Journal of Medicine · 433
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
2022 · Piers Blombery, Ella R. Thompson, et al. · Blood Advances · 91
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
2020 · Victor S. Lin, Thomas E. Lew, et al. · Blood · 89
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
2021 · Piers Blombery, Thomas E. Lew, et al. · Blood · 85
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
2021 · Thomas E. Lew, Victor S. Lin, et al. · Blood Advances · 78
Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies
2018 · Benjamin W. Teh, Constantine S. Tam, et al. · Blood Reviews · 76
Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial
2018 · Anthony R. Mato, Lindsey E. Roeker, et al. · American Journal of Hematology · 69
PDF
BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
2019 · Sasanka M. Handunnetti, Chloe Pek Sang Tang, et al. · Blood · 66
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans
2019 · Gasim Dobie, Fahd A. Kuriri, et al. · Blood Advances · 59
PDF
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma
2019 · Thijs W.H. Flinsenberg, Charnelle C. Tromedjo, et al. · Haematologica · 56
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
2023 · Thomas E Lew, Adrian Minson, et al. · The Lancet Haematology · 39
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
2020 · Thomas E. Lew, Mary Ann Anderson, et al. · Blood Advances · 37
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
2019 · Sasanka M. Handunnetti, Mary Ann Anderson, et al. · Blood · 34
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
2021 · Ella R. Thompson, Tamia Nguyen, et al. · Blood Advances · 27
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
2024 · Sasanka M. Handunnetti, Mary Ann Anderson, et al. · Blood · 25
PDF
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy
2020 · Joanne E. Davis, Sasanka M. Handunnetti, et al. · Blood Advances · 25
PDF
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia
2019 · Benjamin W. Teh, William Chui, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
2024 · Thomas E. Lew, Rory Bennett, et al. · Blood Advances · 22
PDF
Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study
2019 · Sasanka M. Handunnetti, Amit Khot, et al. · Blood · 11
An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies
2019 · Constantine S. Tam, Gavin Cull, et al. · Blood · 10
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
2021 · Sasanka Handunnetti, Mary Ann Anderson, et al. · eJHaem · 9
PDF
High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia
2020 · Ella R Thompson, Tamia Nguyen, et al. · Blood · 9
Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers
2019 · Joanne Davis, Sasanka M Handunnetti, et al. · Blood · 4
Development of a distributed international patient data registry for hairy cell leukemia
2022 · Leslie A. Andritsos, Mirela Anghelina, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
2025 · Sasanka M. Handunnetti, Amit Khot, et al. · Blood Advances · 2
PDF
Works count: 41
Citation count: 1,391
H-index: 18
I10-index: 20
Year
Topic
Type